

# Active substances set

**Search phrase:** linvoseltamab

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

## Multiple myeloma and plasma cell neoplasms

| | | |
|---|---|---|
| **Linvoseltamab** | Linvoseltamab is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least 3 prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy. | NO REIMBURSEMENT<br>ESMO |